EP0180398A1
(en)
|
1984-10-26 |
1986-05-07 |
The Regents Of The University Of California |
Synthesis of beta-lactam
|
CA1305177C
(en)
|
1987-06-30 |
1992-07-14 |
Yasufumi Ohfune |
Carboxycyclopropylglycine and process for producing the same
|
US4904681A
(en)
|
1987-12-01 |
1990-02-27 |
G. D. Searle & Co. |
D-cycloserine and its prodrugs as cognitive enhancers
|
EP0360390A1
(en)
|
1988-07-25 |
1990-03-28 |
Glaxo Group Limited |
Spirolactam derivatives
|
US5061721A
(en)
|
1989-03-15 |
1991-10-29 |
G. D. Searle & Co. |
Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
|
US5086072A
(en)
|
1990-06-18 |
1992-02-04 |
The United States Of America As Represented By The Department Of Health And Human Services |
Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
|
US5350769A
(en)
|
1990-10-30 |
1994-09-27 |
Ss Pharmaceutical Co., Ltd. |
Antiinflammatory gel preparation
|
US5168103A
(en)
|
1991-01-22 |
1992-12-01 |
American Home Products Corporation |
[[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives
|
FR2692268B1
(fr)
|
1992-06-15 |
1994-08-19 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides ayant une activité de récepteur NMDA, acides nucléiques codant pour ces polypeptides et utilisations.
|
SE9301667D0
(sv)
|
1993-05-14 |
1993-05-14 |
Kabi Pharmacia Ab |
New use
|
US5523323A
(en)
|
1993-09-14 |
1996-06-04 |
Maccecchini; Maria-Luisa |
Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
|
US5605911A
(en)
|
1995-01-31 |
1997-02-25 |
Washington University |
Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH)
|
US6335358B1
(en)
|
1995-04-12 |
2002-01-01 |
President And Fellows Of Harvard College |
Lactacystin analogs
|
US5741778A
(en)
|
1996-03-19 |
1998-04-21 |
Amgen Inc. |
Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product
|
US5763393A
(en)
|
1996-05-17 |
1998-06-09 |
Neurotherapeutics L.P. |
Neuroactive peptides
|
NZ332347A
(en)
|
1996-06-07 |
2000-05-26 |
Zeneca Ltd |
Peptide derivatives containing a hydrophobic group, L-amino acid residues and modified L-amino acid residues
|
JP2000503860A
(ja)
|
1996-08-02 |
2000-04-04 |
ザイモジェネティクス,インコーポレイティド |
精巣―特異的インシュリン同族体ポリペプチド
|
US5902815A
(en)
|
1996-09-03 |
1999-05-11 |
Washington University |
Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
|
JP3955345B2
(ja)
|
1996-09-27 |
2007-08-08 |
サントリー株式会社 |
新規アミノ酸ダイジハーベイン
|
AU1585999A
(en)
|
1997-11-12 |
1999-05-31 |
Neurotherapeutics |
Methods for the detection and treatment of disease using a glycosyltransferase
|
US5952389A
(en)
|
1998-01-13 |
1999-09-14 |
Synchroneuron |
Methods of treating tardive dyskinesia and other movement disorders
|
US6007841A
(en)
|
1998-03-13 |
1999-12-28 |
Algos Pharmaceutical Corporation |
Analgesic composition and method for treating pain
|
US6274314B1
(en)
|
1998-04-02 |
2001-08-14 |
Nyxis Neurotherapies, Inc. |
Diagnostic assay for the modified nucleosides pseudouridine, 7-methyladenosine, or 1-methyladenosine
|
US6197820B1
(en)
|
1998-04-06 |
2001-03-06 |
Uab Research Foundation |
Use of phenylglycine derivatives to decrease neuronal death caused by brain tumors and brain lesions
|
US6025471A
(en)
|
1998-06-03 |
2000-02-15 |
Deghenghi; Romano |
Diazaspiro, azepino and azabicyclo therapeutic peptides
|
WO2000027790A1
(en)
|
1998-11-11 |
2000-05-18 |
Smithkline Beecham P.L.C. |
Mutilin compounds
|
AU1724000A
(en)
|
1998-11-12 |
2000-05-29 |
Nyxis, Inc. |
Diagnostic assay for cancer
|
US20030064921A1
(en)
|
1999-10-27 |
2003-04-03 |
The Regents Of The University Of California |
Methods and compounds for modulating melanocortin receptor ligand binding and activity
|
AU1922301A
(en)
|
1999-11-17 |
2001-05-30 |
Nyxis Neurotherapies, Inc. |
Differential gene expression in cancer
|
WO2001057240A2
(en)
|
2000-02-01 |
2001-08-09 |
Agy Therapeutics, Inc. |
Interaction of nmda receptor with protein tyrosine phosphatase
|
JP2001261679A
(ja)
|
2000-03-21 |
2001-09-26 |
Mitsui Chemicals Inc |
ピロリジノン誘導体及びそれらの製造方法並びに該化合物を含有する医薬
|
WO2001096606A2
(en)
|
2000-06-14 |
2001-12-20 |
Nyxis Neurotherapies, Inc. |
Identification of genes and compounds for treatment of cancer
|
EP1296999A2
(en)
|
2000-06-22 |
2003-04-02 |
NYXIS NeuroTherapies, Inc. |
Neuroactive peptides for treatment of hypoxia and related conditions
|
GB0018272D0
(en)
|
2000-07-25 |
2000-09-13 |
Vernalis Research Limited |
Chemical compounds IV
|
EP1186303A3
(en)
|
2000-09-06 |
2003-12-10 |
Pfizer Products Inc. |
Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist
|
IL145209A0
(en)
|
2000-09-06 |
2002-06-30 |
Pfizer Prod Inc |
Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
|
UA73619C2
(en)
|
2000-12-13 |
2005-08-15 |
Pfizer Prod Inc |
Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment
|
WO2002047535A2
(en)
|
2000-12-14 |
2002-06-20 |
Nyxis Neurotherapies, Inc. |
High throughput assay to detect inhibitors of the map kinase pathway
|
WO2002072005A2
(en)
|
2001-03-07 |
2002-09-19 |
University Of Utah Research Foundation |
Linear y-carboxyglutamate rich conotoxins
|
AU2002255705A1
(en)
|
2001-03-12 |
2002-09-24 |
Nyxis Neurotherapies, Inc |
Neuroactive peptides for prevention and/or treatment of hypoxia and neuropathic pain
|
US20030022253A1
(en)
|
2001-07-25 |
2003-01-30 |
Nyxis Neurotherapies, Inc. |
Method for identifying, isolating and producing neuroactive binding agents and binding agents derived thereby
|
NZ551552A
(en)
|
2002-07-05 |
2008-03-28 |
Targacept Inc |
N-Aryl diazaspirocyclic compounds capable of affecting nicotinic cholinergic receptors and methods of preparation and use thereof
|
US7273889B2
(en)
|
2002-09-25 |
2007-09-25 |
Innovative Drug Delivery Systems, Inc. |
NMDA receptor antagonist formulation with reduced neurotoxicity
|
CN100384856C
(zh)
|
2003-04-17 |
2008-04-30 |
麦克公司 |
趋化因子受体活性调节剂杂环基环戊基四氢异喹啉和杂环基环戊基四氢吡啶并吡啶
|
CA2573951A1
(en)
|
2003-07-18 |
2005-01-27 |
Virochem Pharma Inc. |
Spiro compounds and methods for the modulation of chemokine receptor activity
|
EP1660634A4
(en)
|
2003-08-08 |
2009-02-18 |
Burnham Inst |
P16-mediated regulation of NMDA receptors
|
US7662856B2
(en)
|
2003-08-29 |
2010-02-16 |
The University Of Houston System |
Compositions having antimycrobial activity including a hydroxamate or a hydroxamate and a hydroxlyamine
|
GB0323204D0
(en)
|
2003-10-03 |
2003-11-05 |
Novartis Ag |
Organic compounds
|
US20050096311A1
(en)
|
2003-10-30 |
2005-05-05 |
Cns Response |
Compositions and methods for treatment of nervous system disorders
|
JPWO2005047286A1
(ja)
|
2003-11-13 |
2007-05-31 |
小野薬品工業株式会社 |
スピロ複素環化合物
|
RU2355690C2
(ru)
|
2004-01-08 |
2009-05-20 |
Ф.Хоффманн-Ля Рош Аг |
Производные диазаспиропиперидина
|
CN101022801A
(zh)
*
|
2004-08-20 |
2007-08-22 |
塔加西普特公司 |
N-芳基二氮杂螺环化合物在成瘾治疗中的用途
|
US20060063707A1
(en)
|
2004-09-17 |
2006-03-23 |
Lifelike Biomatic, Inc. |
Compositions for enhancing memory and methods therefor
|
CN101090902B
(zh)
|
2004-10-13 |
2013-05-29 |
默沙东公司 |
Cgrp受体拮抗剂
|
ES2428313T3
(es)
|
2005-03-24 |
2013-11-07 |
Emory University |
Métodos para el tratamiento de lesiones del sistema nervioso central mediante un protocolo de administración decreciente
|
WO2007025141A2
(en)
|
2005-08-26 |
2007-03-01 |
Wisconsin Alumni Research Foundation |
Poly-beta-peptides from functionalized beta-lactam monomers and antibacterial compositions containing same
|
AR059224A1
(es)
|
2006-01-31 |
2008-03-19 |
Jerini Ag |
Compuestos para la inhibicion de integrinas y uso de estas
|
WO2007103719A2
(en)
|
2006-03-03 |
2007-09-13 |
Incyte Corporation |
MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
|
CN101583612A
(zh)
|
2006-09-15 |
2009-11-18 |
先灵公司 |
治疗脂质代谢障碍的氮杂环丁酮衍生物
|
JP2008188285A
(ja)
|
2007-02-06 |
2008-08-21 |
Bridgestone Corp |
バックパッド及び車両用シート
|
AU2008228963A1
(en)
|
2007-03-20 |
2008-09-25 |
Vertex Pharmaceuticals Incorporated |
Aminopyrimidines useful as kinase inhibitors
|
CN101066945B
(zh)
|
2007-05-25 |
2010-05-19 |
中国科学院上海有机化学研究所 |
一种合成3-位取代内酰胺类化合物的方法
|
CN101125817B
(zh)
|
2007-08-03 |
2011-09-14 |
中国科学院上海有机化学研究所 |
一种合成高对映选择性醛基取代小环胺类化合物和光学活性3-位取代内酰胺类化合物的方法
|
US20090054392A1
(en)
|
2007-08-20 |
2009-02-26 |
Wyeth |
Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system
|
WO2009039390A2
(en)
|
2007-09-20 |
2009-03-26 |
Naurex Inc. |
The development of glycobiology-based therapeutics for the treatment of brain tumors
|
WO2009105718A1
(en)
|
2008-02-20 |
2009-08-27 |
The Children's Hospital Of Philadelphia |
Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatmemt of autism
|
EP2889028A1
(en)
|
2008-06-24 |
2015-07-01 |
Intervet International B.V. |
Pharmaceutical transdermal compositions and method for treating inflammation in cattle
|
CN102076679A
(zh)
|
2008-06-27 |
2011-05-25 |
神经研究公司 |
新颖的四甲基取代的哌啶衍生物及其作为单胺神经递质再摄取抑制剂的用途
|
CN102112442B
(zh)
|
2008-08-07 |
2014-12-10 |
弗·哈夫曼-拉罗切有限公司 |
制备大环的方法
|
GB0814991D0
(en)
|
2008-08-15 |
2008-09-24 |
Glaxo Group Ltd |
Compounds
|
MX2011003015A
(es)
|
2008-09-18 |
2011-11-18 |
Univ Northwestern |
Moduladores del receptor de n-metil-d-aspartato, y usos de los mismos.
|
WO2010065709A2
(en)
|
2008-12-03 |
2010-06-10 |
Amin Khan |
Hydroxamic acid derivatives, preparation and therapeutic uses thereof
|
DE102009001460B4
(de)
|
2009-03-11 |
2010-12-02 |
Zf Friedrichshafen Ag |
Ölbehälter
|
US8329904B2
(en)
*
|
2009-05-12 |
2012-12-11 |
Hoffmann-La Roche Inc. |
Azacyclic derivatives
|
US20120178695A1
(en)
|
2009-07-02 |
2012-07-12 |
Joseph Moskal |
Methods of treating neuropathic pain
|
RS53513B1
(en)
|
2009-10-05 |
2015-02-27 |
Northwestern University |
GLYX-13 FOR USE IN THE REFRACTOR DEPRESSION TREATMENT PROCEDURE
|
US8951968B2
(en)
|
2009-10-05 |
2015-02-10 |
Northwestern University |
Methods of treating depression and other related diseases
|
US8871208B2
(en)
*
|
2009-12-04 |
2014-10-28 |
Abbvie Inc. |
11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof
|
WO2011076747A1
(en)
|
2009-12-21 |
2011-06-30 |
Novartis Ag |
Diaza-spiro[5.5]undecanes as orexin receptor antagonists
|
US9101612B2
(en)
|
2010-02-11 |
2015-08-11 |
Northwestern University |
Secondary structure stabilized NMDA receptor modulators and uses thereof
|
KR101692275B1
(ko)
|
2010-02-11 |
2017-01-04 |
노오쓰웨스턴 유니버시티 |
2차 구조 안정화된 nmda 수용체 조절제 및 그의 용도
|
UY33227A
(es)
*
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
|
US8097634B2
(en)
|
2010-04-15 |
2012-01-17 |
Hoffmann-La Roche Inc. |
Azacyclic derivatives
|
GB201007789D0
(en)
*
|
2010-05-10 |
2010-06-23 |
Glaxo Group Ltd |
Novel Compound
|
CN102267995A
(zh)
*
|
2010-06-04 |
2011-12-07 |
艾琪康医药科技(上海)有限公司 |
一种制备二氮杂螺环化合物的方法
|
WO2012021712A1
(en)
|
2010-08-12 |
2012-02-16 |
Tetraphase Pharmaceuticals, Inc. |
Tetracycline analogs
|
US9737531B2
(en)
|
2012-07-12 |
2017-08-22 |
Glytech, Llc |
Composition and method for treatment of depression and psychosis in humans
|
WO2012116217A1
(en)
|
2011-02-25 |
2012-08-30 |
Irm Llc |
Compounds and compositions as trk inhibitors
|
KR101893756B1
(ko)
|
2011-03-14 |
2018-09-03 |
베링거 인겔하임 인터내셔날 게엠베하 |
류코트리엔 생성의 벤조디옥산 억제제
|
CA2834286A1
(en)
|
2011-04-27 |
2012-11-01 |
Northwestern University |
Methods of treating alzheimer's disease, huntington's disease, autism, and other disorders
|
WO2013001448A1
(en)
|
2011-06-27 |
2013-01-03 |
Koninklijke Philips Electronics N.V. |
Ultrasound transducer assembly and method of manufacturing the same
|
WO2013010275A1
(en)
|
2011-07-18 |
2013-01-24 |
The Governors Of The University Of Alberta |
Catalysts and processes for the hydrogenation of amides
|
EA029488B1
(ru)
|
2011-07-27 |
2018-04-30 |
Астразенека Аб |
Производные 2-(2,4,5-замещенного анилино)пиримидина в качестве модуляторов egfr, полезных для лечения рака
|
CN103172641B
(zh)
|
2011-12-20 |
2014-06-11 |
钱卫 |
杂环胺基烷氧基取代的喹唑啉衍生物及其用途
|
AR092031A1
(es)
|
2012-07-26 |
2015-03-18 |
Merck Sharp & Dohme |
Inhibidores del canal de potasio medular externo renal
|
CN102936216B
(zh)
|
2012-12-05 |
2015-03-04 |
南京药石药物研发有限公司 |
7,9-二氧代-2,6-氮杂-螺[3.5]壬-2-甲酸叔丁酯及其中间体的制备方法
|
EA032153B1
(ru)
|
2013-01-29 |
2019-04-30 |
Аптиникс Инк. |
Спиролактамные модуляторы nmda-рецептора и их применение
|
LT3514158T
(lt)
|
2013-01-29 |
2023-02-10 |
Aptinyx Inc. |
Spirolaktaminiai nmda receptoriaus moduliatoriai ir jų panaudojimas
|
BR112015018092A2
(pt)
|
2013-01-29 |
2017-07-18 |
Naurex Inc |
moduladores de receptor de nmda de espiro-lactama e usos dos mesmos
|
EA201591404A1
(ru)
|
2013-01-29 |
2016-01-29 |
Аптиникс Инк. |
Спиролактамные модуляторы рецептора nmda и их применение
|
WO2014120800A1
(en)
|
2013-01-29 |
2014-08-07 |
Naurex, Inc. |
Spiro-lactam nmda receptor modulators and uses thereof
|
CN103171641B
(zh)
|
2013-03-19 |
2015-07-15 |
浙江大学 |
具备轮动功能的弹跳机器人
|
JO3517B1
(ar)
*
|
2014-01-17 |
2020-07-05 |
Novartis Ag |
ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
|
GB2528480A
(en)
|
2014-07-23 |
2016-01-27 |
Givaudan Sa |
Improvements in or relating to organic compounds
|
GB201416346D0
(en)
|
2014-09-16 |
2014-10-29 |
Shire Internat Gmbh |
Spirocyclic derivatives
|
MX2018014202A
(es)
|
2016-05-19 |
2019-06-20 |
Aptinyx Inc |
Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos.
|
WO2017201285A1
(en)
|
2016-05-19 |
2017-11-23 |
Aptinyx Inc. |
Spiro-lactam nmda receptor modulators and uses thereof
|
MX2019001322A
(es)
|
2016-08-01 |
2019-09-11 |
Aptinyx Inc |
Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos.
|
AU2017306152A1
(en)
|
2016-08-01 |
2019-01-31 |
Aptinyx Inc. |
Spiro-lactam NMDA receptor modulators and uses thereof
|
AU2017305240B2
(en)
|
2016-08-01 |
2021-12-09 |
Aptinyx Inc. |
Spiro-lactam NMDA receptor modulators and uses thereof
|
BR112019001923A2
(pt)
|
2016-08-01 |
2019-05-14 |
Aptinyx Inc. |
moduladores de nmda de espiro-lactama e métodos de sua utilização
|
PE20190500A1
(es)
|
2016-08-01 |
2019-04-10 |
Aptinyx Inc |
Moduladores del receptor nmda spiro-lactam y uso de los mismos
|
JP7210599B2
(ja)
|
2018-01-31 |
2023-01-23 |
アプティニックス インコーポレイテッド |
スピロラクタム系nmda受容体修飾因子およびその使用
|
SG11202007251XA
(en)
|
2018-01-31 |
2020-08-28 |
Aptinyx Inc |
Spiro-lactam nmda receptor modulators and uses thereof
|
US12012413B2
(en)
|
2019-11-11 |
2024-06-18 |
Tenacia Biotechnology (Hong Kong) Co., Limited |
Methods of treating painful diabetic peripheral neuropathy
|
US20210308101A1
(en)
|
2019-11-11 |
2021-10-07 |
Aptinyx Inc. |
Methods of treating fibromyalgia
|
WO2021112987A1
(en)
|
2019-12-04 |
2021-06-10 |
Aptinyx Inc. |
Methods of treating cognitive impairment associated with neurodegenerative disease
|